AmCham EU stands in solidarity with the European Commission’s Beating Cancer Plan

Cancer is the second leading cause of death worldwide. In Europe, 2.6 million people are diagnosed with cancer every year, with nearly half of that number succumbing to the disease. If decisive action is not taken, then by 2035, approximately 40% of Europeans can expect to face cancer in their lifetime.

On this year’s World Cancer Day, AmCham EU stands in solidarity with the European Commission’s Beating Cancer Plan. Several of our member companies directly contribute to the fight against cancer providing innovative solutions in the form of cancer treatments or developing the medical devices used in cancer diagnosis.

News
3 Feb 2021
Healthcare
AmCham EU stands in solidarity with the European Commission’s Beating Cancer Plan

Cancer is the second leading cause of death worldwide. In Europe, 2.6 million people are diagnosed with cancer every year, with nearly half of that number succumbing to the disease. If decisive action is not taken, then by 2035, approximately 40% of Europeans can expect to face cancer in their lifetime.

On this year’s World Cancer Day, AmCham EU stands in solidarity with the European Commission’s Beating Cancer Plan. Several of our member companies directly contribute to the fight against cancer providing innovative solutions in the form of cancer treatments or developing the medical devices used in cancer diagnosis.

With this ambitious plan, the EU has devised a four-pillar approach to overcome cancer as a leading cause of death. These are:

  • prevention;

  • early detection;

  • diagnosis and treatment; and

  • quality of life of cancer patients and survivors.

AmCham EU shares the European Commission’s ambition to take on cancer. A holistic approach that encompasses the entire disease pathway, while engaging the full arsenal of the life sciences sector in the fight, can help to improve the survival chances of cancer patients, while reducing the number of cases.

Check out our explainer of Europe’s Beating Cancer Plan.

Related items

News
27 Oct 2025

Advancing EU health policy through competitiveness and innovation

On Monday, 27 October, AmCham EU met with Lorena Boix-Alonso, Deputy Director-General, Directorate-General for Health and Food Safety, European Commission, for an exchange on the role of health policy in strengthening the EU’s competitiveness. The discussion focused on how to foster innovation while ensuring patient safety, as well as ways to streamline the legislative framework to improve efficiency and uphold high standards of care. AmCham EU highlighted the importance of evidence-based, future-proof regulation that supports a resilient health system and drives innovation. Continued dialogue is essential to advancing shared goals for Europe’s health agenda. 

Healthcare
Read more
Read more about Advancing EU health policy through competitiveness and innovation
News
9 Oct 2025

Advancing European healthcare in Strasbourg

From Tuesday, 7 to Wednesday, 8 October, AmCham EU travelled to the European Parliament in Strasbourg, France to engage with MEPs on the future of EU health policy. In meetings with over a dozen policymakers, members underscored the importance of a competitive, innovation-driven life sciences sector that ensures timely patient access to medicines and technologies. The discussions also covered the General Pharmaceutical Legislation, the Medical Devices Regulation, the Critical Medicines Act and the upcoming Biotech Act. The delegation called for evidence-based, proportionate policies that promote regulatory coherence and support Europe’s global leadership in health innovation. 

Healthcare
Read more
Read more about Advancing European healthcare in Strasbourg
How the Critical Medicines Act will strengthen Europe’s life sciences sector
News
4 May 2025

How the Critical Medicines Act will strengthen Europe’s life sciences sector

On Wednesday, 30 April, Thibaut L'Ortye, Senior Director of Public Affairs, AmCham EU, joined a panel discussion on the Critical Medicines Act (CMA). Hosted by the European Policy Centre, Mr L'Ortye underlined the need for open and resilient supply chains to ensure continued access to medicines. He also highlighted the CMA’s potential to strengthen Europe's competitiveness and improve patient access. Avoiding protectionist measures and aligning the CMA with the EU’s wider simplification efforts is essential to attract investment into the Single Market. The discussion highlighted the importance of public-private collaboration to build a more competitive life sciences sector in the EU. 

Healthcare
Read more
Read more about How the Critical Medicines Act will strengthen Europe’s life sciences sector